In vitro characterization and performance testing of the Ension pediatric cardiopulmonary assist system

George M. Pantalos, Tim Horrell, Tracey Merkley, Sarina Sahetya, Jeff Speakman, Greg Johnson, Mark Gartner

Research output: Contribution to journalArticle

Abstract

In the last 40 years, mechanical circulatory support devices have become an effective option for the treatment of end-stage heart failure in adults. Few possibilities, however, are available for pediatric cardiopulmonary support. Ension Inc. (Pittsburgh, PA) is developing a pediatric cardiopulmonary assist system (pCAS) intended to address the limitations of existing devices used for this patient population. The pCAS device is an integrated unit containing an oxygenator and pump within a single casing, significantly reducing the size and blood-contacting surface area in comparison to current devices. Prototype pCAS devices produce appropriate flows and pressures while minimizing priming volume and preparation time. The pCAS was tested on a mock circulation designed to approximate the hemodynamic parameters of a small infant using a 10-Fr. extracorporeal membrane oxygenation inflow cannula and an 8-Fr. extracorporeal membrane oxygenation outflow cannula. Revision 4 of the device provided a flow rate of 0.42 L/min at 6,500 RPM. Revision 5, featuring improved impeller and diffuser designs, provided a flow rate of 0.57 L/min at 5,000 RPM. The performance tests indicate that for this cannulae combination, the pCAS pump is capable of delivering sufficient flows for patients <5 kg.

Original languageEnglish (US)
Pages (from-to)282-286
Number of pages5
JournalASAIO Journal
Volume55
Issue number3
DOIs
StatePublished - May 1 2009
Externally publishedYes

Fingerprint

Pediatrics
Equipment and Supplies
Testing
Extracorporeal Membrane Oxygenation
Oxygenation
Flow rate
Oxygenators
Pumps
Membranes
Hemodynamics
In Vitro Techniques
Blood
Heart Failure
Pressure
Population
Cannula

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

In vitro characterization and performance testing of the Ension pediatric cardiopulmonary assist system. / Pantalos, George M.; Horrell, Tim; Merkley, Tracey; Sahetya, Sarina; Speakman, Jeff; Johnson, Greg; Gartner, Mark.

In: ASAIO Journal, Vol. 55, No. 3, 01.05.2009, p. 282-286.

Research output: Contribution to journalArticle

Pantalos, GM, Horrell, T, Merkley, T, Sahetya, S, Speakman, J, Johnson, G & Gartner, M 2009, 'In vitro characterization and performance testing of the Ension pediatric cardiopulmonary assist system', ASAIO Journal, vol. 55, no. 3, pp. 282-286. https://doi.org/10.1097/MAT.0b013e3181909d76
Pantalos, George M. ; Horrell, Tim ; Merkley, Tracey ; Sahetya, Sarina ; Speakman, Jeff ; Johnson, Greg ; Gartner, Mark. / In vitro characterization and performance testing of the Ension pediatric cardiopulmonary assist system. In: ASAIO Journal. 2009 ; Vol. 55, No. 3. pp. 282-286.
@article{d862659fe54b4b128dc5860fadb99031,
title = "In vitro characterization and performance testing of the Ension pediatric cardiopulmonary assist system",
abstract = "In the last 40 years, mechanical circulatory support devices have become an effective option for the treatment of end-stage heart failure in adults. Few possibilities, however, are available for pediatric cardiopulmonary support. Ension Inc. (Pittsburgh, PA) is developing a pediatric cardiopulmonary assist system (pCAS) intended to address the limitations of existing devices used for this patient population. The pCAS device is an integrated unit containing an oxygenator and pump within a single casing, significantly reducing the size and blood-contacting surface area in comparison to current devices. Prototype pCAS devices produce appropriate flows and pressures while minimizing priming volume and preparation time. The pCAS was tested on a mock circulation designed to approximate the hemodynamic parameters of a small infant using a 10-Fr. extracorporeal membrane oxygenation inflow cannula and an 8-Fr. extracorporeal membrane oxygenation outflow cannula. Revision 4 of the device provided a flow rate of 0.42 L/min at 6,500 RPM. Revision 5, featuring improved impeller and diffuser designs, provided a flow rate of 0.57 L/min at 5,000 RPM. The performance tests indicate that for this cannulae combination, the pCAS pump is capable of delivering sufficient flows for patients <5 kg.",
author = "Pantalos, {George M.} and Tim Horrell and Tracey Merkley and Sarina Sahetya and Jeff Speakman and Greg Johnson and Mark Gartner",
year = "2009",
month = "5",
day = "1",
doi = "10.1097/MAT.0b013e3181909d76",
language = "English (US)",
volume = "55",
pages = "282--286",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - In vitro characterization and performance testing of the Ension pediatric cardiopulmonary assist system

AU - Pantalos, George M.

AU - Horrell, Tim

AU - Merkley, Tracey

AU - Sahetya, Sarina

AU - Speakman, Jeff

AU - Johnson, Greg

AU - Gartner, Mark

PY - 2009/5/1

Y1 - 2009/5/1

N2 - In the last 40 years, mechanical circulatory support devices have become an effective option for the treatment of end-stage heart failure in adults. Few possibilities, however, are available for pediatric cardiopulmonary support. Ension Inc. (Pittsburgh, PA) is developing a pediatric cardiopulmonary assist system (pCAS) intended to address the limitations of existing devices used for this patient population. The pCAS device is an integrated unit containing an oxygenator and pump within a single casing, significantly reducing the size and blood-contacting surface area in comparison to current devices. Prototype pCAS devices produce appropriate flows and pressures while minimizing priming volume and preparation time. The pCAS was tested on a mock circulation designed to approximate the hemodynamic parameters of a small infant using a 10-Fr. extracorporeal membrane oxygenation inflow cannula and an 8-Fr. extracorporeal membrane oxygenation outflow cannula. Revision 4 of the device provided a flow rate of 0.42 L/min at 6,500 RPM. Revision 5, featuring improved impeller and diffuser designs, provided a flow rate of 0.57 L/min at 5,000 RPM. The performance tests indicate that for this cannulae combination, the pCAS pump is capable of delivering sufficient flows for patients <5 kg.

AB - In the last 40 years, mechanical circulatory support devices have become an effective option for the treatment of end-stage heart failure in adults. Few possibilities, however, are available for pediatric cardiopulmonary support. Ension Inc. (Pittsburgh, PA) is developing a pediatric cardiopulmonary assist system (pCAS) intended to address the limitations of existing devices used for this patient population. The pCAS device is an integrated unit containing an oxygenator and pump within a single casing, significantly reducing the size and blood-contacting surface area in comparison to current devices. Prototype pCAS devices produce appropriate flows and pressures while minimizing priming volume and preparation time. The pCAS was tested on a mock circulation designed to approximate the hemodynamic parameters of a small infant using a 10-Fr. extracorporeal membrane oxygenation inflow cannula and an 8-Fr. extracorporeal membrane oxygenation outflow cannula. Revision 4 of the device provided a flow rate of 0.42 L/min at 6,500 RPM. Revision 5, featuring improved impeller and diffuser designs, provided a flow rate of 0.57 L/min at 5,000 RPM. The performance tests indicate that for this cannulae combination, the pCAS pump is capable of delivering sufficient flows for patients <5 kg.

UR - http://www.scopus.com/inward/record.url?scp=67650363672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650363672&partnerID=8YFLogxK

U2 - 10.1097/MAT.0b013e3181909d76

DO - 10.1097/MAT.0b013e3181909d76

M3 - Article

VL - 55

SP - 282

EP - 286

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 3

ER -